{"url_path":"/sec/abt/8-k/2026-04-27/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 ****Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1800/0001104659-26-049434-index.html","accession_number":"0001104659-26-049434","cik":"0000001800","ticker":"ABT","issuer_name":"ABBOTT LABORATORIES","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800/0001104659-26-049434-index.html","primary_entity_key":"0000001800","primary_entity_name":"ABBOTT LABORATORIES"},"word_count":353,"has_tables":true,"body_markdown":"**Item 5.02****Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory\nArrangements of Certain Officers.**\n\n \n\nOn April 24, 2026, Kevin Conroy was named to the Abbott\nLaboratories’ (“Abbott”) Board of Directors.\n\n \n\nOn April 24, 2026, Abbott\nshareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual\nMeeting of Shareholders. The 2026 Program was adopted by Abbott’s Board of Directors on February 20, 2026, subject to shareholder\napproval at the Annual Meeting. The 2026 Program replaces the Abbott Laboratories 2017 Incentive Stock Program, as amended and restated\n(the “2017 Program”), under which Abbott makes all of its equity-related incentive compensation awards.\n\n \n\nThe 2026 Program, which is administered by the Compensation Committee of Abbott’s Board of Directors, permits Abbott to grant nonqualified\nstock options, restricted stock awards, restricted stock units, performance awards, and other share-based awards (including stock appreciation\nrights, dividend equivalents and recognition awards) to non-employee directors and employees of Abbott and its subsidiaries. Subject to\nadjustment in the event of changes in capitalization, the maximum number of Abbott common shares that may be issued under the 2026 Program\nis 140,000,000, plus the number of shares that cease to be subject to awards under the 2017 Program due to forfeiture, expiration, cancellation,\nor cash settlement and shares withheld to satisfy tax withholding obligations under outstanding 2017 Program full value awards; and less\nthe number of shares subject to awards granted under the 2017 Program between March 1, 2026 and April 23, 2026, with each full value award\nshare being counted as three shares against the 2017 Program’s share reserve. The 2026 Program has a term of ten years.\n\n \n\nFor a more detailed description of the 2026 Program, see pages 79 through\n86 of Abbott’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on March 13, 2026.\nThe foregoing descriptions are qualified in their entirety by the full text of the 2026 Program, which was included as Exhibit A to the\nproxy statement and is incorporated by reference into this Current Report on Form 8-K as Exhibit 10.1."}